FDA Approves Semaglutide, Novo Nordisk’s Once-Weekly GLP-1 for Type 2 Diabetes
December 7th, 2017
Semaglutide, Novo Nordisk’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes (T2D), received FDA approval Tuesday, after beating its rival in a head-to-head
